-
Retrospective comparison of a weight-based dose every 2 weeks with a fixed dose every month: a real-life analysis of nivolumab in the treatment of advanced melanoma. Melanoma Res. (IF 2.2) Pub Date : 2024-03-15 Marie Leroy, Eve Desmedt, Laure Deramoudt, Michèle Vasseur, Pascal Odou, Hélène Béhal, Bertrand Décaudin, Laurent Mortier, Nicolas Simon
Nivolumab was first authorized at a weight-based dose (WBD) of 3 mg/kg every two weeks (Q2W). Since 2017, a fixed dose (FD) regimen [first 240 mg Q2W and then 480 mg per month (Q4W)] was allowed. The objective of the study was to compare a WBD regimen and an FD regimen with regard to effectiveness and safety. We conducted a single-center, retrospective, real-life study of consecutive adult patients
-
Feasibility and efficacy of indocyanine green in monitoring systemic drug leakage during isolated limb perfusion for recurrent melanoma of extremity. Melanoma Res. (IF 2.2) Pub Date : 2024-03-15 Sri Siddharth Nekkanti, Syed Nusrath, Rajesh Jarang, Basanth Kumar Rayani, Yerramshetty Vamshi Krishna, Kalidindi Venkata Vijaya Narsimha Raju
Melanoma is known for its high metastatic potential and aggressive growth. Recurrence is common post-surgery, sometimes leading to unresectable disease. Locally recurrent unresectable melanoma of extremity has been treated with high-dose anticancer chemotherapy via isolated limb perfusion (ILP) to improve local efficacy of drug and salvage limbs. Standard ILP monitoring uses radiolabeled dyes, requiring
-
Genetic causal relationship between gut microbiota and cutaneous melanoma: a two-sample Mendelian randomization study. Melanoma Res. (IF 2.2) Pub Date : 2024-03-11 Peizhou Wang, Tun Liu, Qingguo Zhang, Pan Luo
Currently, numerous studies suggest a potential association between the gut microbiota and the progression of melanoma. Hence, our objective was to examine the genetic impact of the gut microbiota on melanoma through the utilization of the Mendelian randomization (MR) approach. This research employed Bacteroides, Streptococcus, Proteobacteria, and Lachnospiraceae as exposure variables and cutaneous
-
What matters most to people with metastatic uveal melanoma? A qualitative study to inform future measurement of health-related quality of life. Melanoma Res. (IF 2.2) Pub Date : 2024-03-05 Carrie-Anne Ng, Tim Luckett, Brendan Mulhern, Damien Kee, Julia Lai-Kwon, Anthony M Joshua
Metastatic uveal melanoma (mUM) is a rare cancer with poor prognosis, but novel treatments are emerging. Currently, there are no mUM-specific health-related quality of life (HRQL) questionnaires available for clinical research. We aimed to explore how mUM and its treatment affect HRQL and assess the content validity of existing questionnaires.
-
Global trends in cutaneous malignant melanoma incidence and mortality. Melanoma Res. (IF 2.2) Pub Date : 2024-02-21 Giuseppe De Pinto, Silvia Mignozzi, Carlo La Vecchia, Fabio Levi, Eva Negri, Claudia Santucci
Mortality from cutaneous malignant melanoma (CMM) increased in the past, but trends have been favorable in more recent years in several high-income countries. However, incidence has been increasing in several countries. We provided an up-to-date overview of mortality trends from CMM. We analyzed death certification data from the WHO in selected countries worldwide from 1980 to the most recent available
-
Machine learning developed an intratumor heterogeneity signature for predicting prognosis and immunotherapy benefits in skin cutaneous melanoma. Melanoma Res. (IF 2.2) Pub Date : 2024-02-16 Wei Zhang, Shuai Wang
Intratumor heterogeneity (ITH) is defined as differences in molecular and phenotypic profiles between different tumor cells and immune cells within a tumor. ITH was involved in the cancer progression, aggressiveness, therapy resistance and cancer recurrence.
-
Immunohistochemistry assessment of tissue neutrophil-to-lymphocyte ratio (tNLR) predicts outcomes in melanoma patients treated with anti-programmed cell death 1 therapy. Melanoma Res. (IF 2.2) Pub Date : 2024-02-16 Renan J Teixeira, Vinícius G de Souza, Bruna P Sorroche, Victor G Paes, Fabiana A Zambuzi-Roberto, Caio A D Pereira, Vinicius L Vazquez, Lidia M R B Arantes
Elevated neutrophil-to-lymphocyte ratio (NLR) is associated with diminished immunotherapy response in metastatic melanoma. Although NLR assessment in peripheral blood is established, tissue dynamics remain insufficiently explored. This study aimed to evaluate tissue NLR (tNLR)'s predictive potential through immunohistochemistry in immunotherapy-treated melanoma. Fifty melanoma patients who underwent
-
Clinical and genetic determinants of vitamin D receptor expression in cutaneous melanoma patients. Melanoma Res. (IF 2.2) Pub Date : 2024-02-13 Julie De Smedt, Claudia Aura, Sofie Van Kelst, Laudine Janssen, Vivien Marasigan, Veerle Boecxstaens, Marguerite Stas, Kris Bogaerts, Ann Belmans, Isabelle Cleynen, Dirk Vanderschueren, Katleen Vandenberghe, Oliver Bechter, Arjen Nikkels, Tinne Strobbe, Gabriella Emri, Dieter Lambrechts, Marjan Garmyn
Decrease of vitamin D receptor (VDR) expression is observed in melanocytic naevi and melanoma compared to normal skin. Little is known about factors influencing VDR expression in cutaneous melanoma (CM). We investigated the correlation of VDR expression in CM with 25-hydroxy vitamin D (25OHD) levels, demographic/clinical parameters, genetic variants of VDR and pathology of the primary tumor. Demographic/clinical
-
Hypoxic transcriptomes predict survival and tumor-infiltrating immune cell composition in cutaneous melanoma. Melanoma Res. (IF 2.2) Pub Date : 2024-02-07 Michael J Diaz, Jessica Quach, Joanna Song, Silvija Milanovic, Jasmine T Tran, Lauren C Ladehoff, Sai Batchu, Patrick Whitman, Benajmin H Kaffenberger, Marjorie E Montanez-Wiscovich
Hypoxia has established associations with aggressive tumor phenotypes in many cancers. However, it is not currently understood whether tumor hypoxia levels map to distinct immune infiltrates in cutaneous melanoma, potentially unveiling novel therapeutic targets. To this end, we leveraged a previously identified seven-gene hypoxia signature to grade hypoxia levels of 460 cutaneous melanomas obtained
-
Neonatal cutaneous melanoma with cutaneous metastasis: a case report and review of literature. Melanoma Res. (IF 2.2) Pub Date : 2024-02-07 Alp Ercan, Can Ege Yalçin
Malignant melanoma, a rare skin cancer in children, primarily affects individuals over 10 years old. Giant congenital nevi, found in about 1% of newborns, increases the risk. However, the development of melanoma from a pre-existing giant congenital nevus diagnosed during the neonatal period is exceptionally rare. We present a case of congenital melanoma in a newborn, where nodules grew on an existing
-
Relevance of detection of RAF fusion transcripts in pan-negative melanoma in routine practice. Melanoma Res. (IF 2.2) Pub Date : 2024-02-07 Guillaume Delzenne, Marie Boileau, Philippe Jamme, Olivier Farchi, Laurent Mortier
Pan-negative melanomas account for 30% of melanomas. In case of immunotherapy failure, therapeutic options are limited. Oncogene fusions represent a target of interest in many solid cancers. In melanoma, the frequency of oncogene fusion is not well documented and not routinely investigated.
-
Pregnancy-associated melanoma: characteristics and outcomes from 2002 to 2020. Melanoma Res. (IF 2.2) Pub Date : 2024-01-23 Tara M Davidson, Tina J Hieken, Amy E Glasgow, Elizabeth B Habermann, Yiyi Yan
Melanoma diagnosed within 1 year of pregnancy is defined as pregnancy-associated melanoma (PAM). No robust data on how pregnancy influences melanoma nor guidelines for PAM management exist. With IRB approval, female patients with a pathology-confirmed melanoma diagnosis within 1 year of pregnancy treated at our institution from 2000 to 2020 were identified. Controls from the cancer registry were matched
-
The effect of microRNA-9 overexpression on inhibition of melanoma cancer stem cells tumorigenicity. Melanoma Res. (IF 2.2) Pub Date : 2024-01-15 Sahranavardfard Parisa, Izadpanah Amirhossein, Yasavoli-Sharahi Hamed, Firouzi Javad, Azimi Masoumeh, Khosravani Pardis, Dorraj Mahshad, Keighobadi Faezeh, Marzieh Ebrahimi
Most of the studies have reported the downregulation of miR-9 in metastatic melanomas compared to primary tumors. They indicated that miR-9 negatively regulates the epithelial-to-mesenchymal transition (EMT) by inhibiting SNAIL1 expression and consequently promotes CDH1 expression. Since the process of EMT is associated to stem cell features, it could be interesting to study the effect of miR-9 on
-
Simultaneous melanomas in the setting of multiple primary melanomas. Melanoma Res. (IF 2.2) Pub Date : 2024-01-15 Maria Kostaki, Michaela Plaka, Aggeliki Befon, Clio Dessinioti, Katerina Kypraiou, Vasiliki Chardalia, Eleftheria Christofidou, Doris Polydorou, Alexandros Stratigos
It is estimated that about 1-13% of melanoma patients will develop multiple primary melanomas. Although the occurrence of subsequent tumors has been described during the last few years, the development of simultaneous melanomas has not yet been extensively studied. We reviewed our registries to identify patients with multiple primary melanomas. We studied epidemiological, clinical, and histological
-
Evaluating the efficacy of combination and single-agent immunotherapies in real-world patterns of disease progression and survival of metastatic melanoma patients. Melanoma Res. (IF 2.2) Pub Date : 2024-01-05 Brian Ko, Kevin Tao, Lachlan Brennan, Swanand Rakhade, Cynthia X Chan, Jee-Young Moone, Richard Zhu, Ariel Sher, Samuel Wang, Yadriel Bracero, Ben Fullerton, Beth McLellan, Larisa J Geskin, Yvonne M Saenger
To describe survival outcomes in patients with metastatic melanoma in a real-world setting receiving combination and single-agent immunotherapy outside the clinical trial context. We conducted a retrospective single-institution study of patients with metastatic melanoma in a real-world setting. Survival was calculated using log-rank test. Contingency tables were analyzed using Fisher's Exact test.
-
The role of artificial intelligence and convolutional neural networks in the management of melanoma: a clinical, pathological, and radiological perspective. Melanoma Res. (IF 2.2) Pub Date : 2023-12-22 Joshua Yee, Cliff Rosendahl, Lauren G Aoude
Clinical dermatoscopy and pathological slide assessment are essential in the diagnosis and management of patients with cutaneous melanoma. For those presenting with stage IIC disease and beyond, radiological investigations are often considered. The dermatoscopic, whole slide and radiological images used during clinical care are often stored digitally, enabling artificial intelligence (AI) and convolutional
-
Combined PDE4+MEK inhibition shows antiproliferative effects in NRASQ61 mutated melanoma preclinical models. Melanoma Res. (IF 2.2) Pub Date : 2023-12-22 Baptiste Louveau, Coralie Reger De Moura, Fanélie Jouenne, Aurélie Sadoux, Clara Allayous, Laetitia Da Meda, Mélanie Bernard-Cacciarella, Barouyr Baroudjian, Céleste Lebbé, Samia Mourah, Nicolas Dumaz
Upregulation of phosphodiesterase type 4 (PDE4) has been associated with worse prognosis in several cancers. In melanomas harboring NRAS mutations, PDE4 upregulation has been shown to trigger a switch in signaling from BRAF to RAF1 which leads to mitogen-activated protein kinase pathway activation. Previous in vitro evidence showed that PDE4 inhibition induced death in NRASQ61mut melanoma cells and
-
Patterns of radiological response to tebentafusp in patients with metastatic uveal melanoma. Melanoma Res. (IF 2.2) Pub Date : 2023-12-19 Natalia M Roshardt Prieto, Patrick Turko, Caroline Zellweger, Thi Dan Linh Nguyen-Kim, Ramon Staeger, Elisa Bellini, Mitchell P Levesque, Reinhard Dummer, Egle Ramelyte
Metastatic uveal melanoma (mUM) is a rare type of melanoma with poor outcomes. The first systemic treatment to significantly prolong overall survival (OS) in patients with mUM was tebentafusp, a bispecific protein that can redirect T-cells to gp-100 positive cells. However, the objective response rate according to Response Evaluation Criteria in Solid Tumors (RECIST) may underestimate the clinical
-
Dabrafenib plus trametinib in unselected advanced BRAF V600-mut melanoma: a non-interventional, multicenter, prospective trial. Melanoma Res. (IF 2.2) Pub Date : 2023-12-13 Erika Richtig, Van A Nguyen, Peter Koelblinger, Ingrid Wolf, Helmut Kehrer, Werner Saxinger, Julia M Ressler, Georg Weinlich, Damian Meyersburg, Christine Hafner, Elisabeth Jecel-Grill, Julian Kofler, Bernhard Lange-Asschenfeldt, Felix Weihsengruber, Klemens Rappersberger, Nina Svastics, Klaus Gasser, Arno Seeber, Franz Kratochvill, Sophie Nagler, Bernhard Mraz, Christoph Hoeller
The efficacy of combined BRAF and MEK inhibition for BRAF V600-mutant melanoma in a broad patient population, including subgroups excluded from phase 3 trials, remains unanswered. This noninterventional study (DATUM-NIS) assessed the real-world efficacy, safety and tolerability of dabrafenib plus trametinib in Austrian patients with unresectable/metastatic melanoma.
-
Real-world management practices and characteristics of patients with advanced melanoma initiated on immuno-oncology or targeted therapy in the first-line setting during the period 2015-2018 in Greece. The 'SUMMER' study: a retrospective multicenter chart review project. Melanoma Res. (IF 2.2) Pub Date : 2023-12-13 Dimitrios Bafaloukos, Panagiotis Kouzis, Panagiotis Gouveris, Ioannis Boukovinas, Konstantinos Kalbakis, Sofia Baka, Georgios Kyriakakis, Despoina Moschou, Aristea Molfeta, Stamatia Demiri, Dimitrios Mavroudis, Spanoudi Filio, Ioannis Dimitriadis, Helen Gogas
This study primarily aimed to generate real-world evidence (RWE) on the profile and first-line treatment (1LT) patterns of patients with advanced (unresectable Stage III/metastatic) cutaneous melanoma initiated on immuno-oncology (IO)- or targeted therapy (TT)-based 1LT between 1 January 2015 and 1 January 2018 (index period), in routine settings of Greece. This was a multicenter, retrospective chart
-
Development and validation of a nomogram for elderly patients with ulcerative melanoma. Melanoma Res. (IF 2.2) Pub Date : 2023-12-13 Jie Yan, Haiyan Wang, Xiaoou Lu, Fengjuan Li
The current state of survival prediction models for elderly patients with ulcerative melanoma (uCM) is limited. We sought to develop a nomogram model that can predict overall survival of geriatric patients with uCM. The Surveillance, Epidemiology, and End Results (SEER) database served as a source for patients diagnosed with uCM between 2004 and 2015. Statistical analyses were conducted to determine
-
Targeting beta-adrenergic receptor pathways in melanoma: how stress modulates oncogenic immunity. Melanoma Res. (IF 2.2) Pub Date : 2023-12-04 Benjamin Switzer, Igor Puzanov, Shipra Gandhi, Elizabeth A Repasky
The intricate pathways of the sympathetic nervous system hold an inherently protective role in the setting of acute stress. This is achieved through dynamic immunomodulatory and neurobiological networks. However, excessive and chronic exposure to these stress-induced stimuli appears to cause physiologic dysfunction through several mechanisms that may impair psychosocial, neurologic, and immunologic
-
Quality of life after melphalan percutaneous hepatic perfusion for patients with metastatic Uveal Melanoma. Melanoma Res. (IF 2.2) Pub Date : 2023-12-01 Ganesh Vigneswaran, Weeratunge Malalasekera, Victoria Smith, Tom Gibson, Shian Patel, Matthew Wheater, Ioannis Karydis, Sanjay Gupta, Brian Stedman, Sachin Modi
Recent studies indicate that melphalan percutaneous hepatic perfusion (M-PHP) for liver metastases from ocular melanoma (mUM) improves survival. Importantly, this benefit must be carefully balanced with changes in a patient's quality of life (QoL). This study examines the QoL changes post-M-PHP.
-
Real-world relapse-free survival data on adjuvant anti-PD-1 therapy for patients with newly diagnosed and recurrent stage III melanoma. Melanoma Res. (IF 2.2) Pub Date : 2023-11-28 Emma H A Stahlie, Lisanne P Zijlker, Michel W J M Wouters, Yvonne M Schrage, Winan J van Houdt, Alexander C J van Akkooi
We aimed to compare the relapse-free survival (RFS) in patients treated with adjuvant anti-programmed cell death-1 (anti-PD-1) therapy for a first diagnosis of stage III melanoma to patients treated after resection of the recurrences. Patients treated with adjuvant anti-PD-1 therapy after complete resection of stage III melanoma between September 2018 and January 2021, were included. Depending on when
-
Small-vessel vasculitis leading to severe acute kidney injury after ipilimumab: a case report. Melanoma Res. (IF 2.2) Pub Date : 2023-11-28 Rui Duarte, Filipa Trigo, Ivan Luz, Paulo Santos
Immune checkpoint inhibitors are effective monoclonal antibodies used in cancer treatment, particularly in metastatic melanoma. They target proteins responsible for cancer cells evading the immune system. However, their use can lead to immune-related adverse events, with the skin and gastrointestinal tract being commonly affected. Kidney involvement is rarer, with interstitial nephritis being the most
-
Effectiveness, safety and utilization of cobimetinib and vemurafenib in patients with BRAF V600 mutant melanoma with and without cerebral metastasis under real-world conditions in Germany: the non-interventional study coveNIS. Melanoma Res. (IF 2.2) Pub Date : 2023-11-13 Katharina C Kähler, Dirk Debus, Gaston Schley, Daniela Göppner, Jessica C Hassel, Friedegund Meier, Patrick Terheyden, Rudolf Stadler, Thomas Tüting, Martin Kaatz, Norman-Philipp Hoff, Ehsan Masoudi, Agnieszka Zdanowicz-Specht, Minh Tam Nguyen, Peter Mohr
Cobimetinib/vemurafenib combination therapy is approved for treatment of adults with unresectable or metastatic BRAF V600 mutated malignant melanoma (mM). The non-interventional post-authorisation safety study coveNIS collected real-world data on cobimetinib/vemurafenib treatment focussing on overall survival (OS), safety and utilization. MM patients with brain metastases are usually excluded from
-
Tumour regression predicts better response to interferon therapy in melanoma patients: a retrospective single centre study. Melanoma Res. (IF 2.2) Pub Date : 2023-11-13 Noémi E Mezőlaki, Eszter Baltás, Henriette L Ócsai, Anita Varga, Irma Korom, Erika Varga, István B Németh, Erika G Kis, János Varga, Ádám Kocsis, Rolland Gyulai, Mátyás Bukva, Lajos Kemény, Judit Oláh
We hypothesise that regression may have an impact on the effectiveness of adjuvant IFN therapy, based on its role in the host immune response. Our purpose is to investigate regression and ulceration as prognostic factors in case of interferon-alpha (IFN)-treated melanoma patients. We followed 357 IFN-treated melanoma patients retrospectively, investigating progression-free survival (PFS) and overall
-
Management of metastatic bone disease of melanoma. Melanoma Res. (IF 2.2) Pub Date : 2023-11-08 Wenyan Chen, Chen Yang, Biqi Chen, Mian Xi, Baoqing Chen, Qiaoqiao Li
One of the most aggressive tumors arising from the skin, mucosa, and uvea is malignant melanoma, which easily metastasizes. Bone tissue is one of the most typical locations for distant metastasis, and around 5%-20% of patients eventually acquired skeletal metastases. For decades, the incidence of bone metastases was higher, bringing greater burden on the family, society, and healthcare system owing
-
Bone marrow metastases: a systematic review of a neglected involvement in malignant melanoma. Melanoma Res. (IF 2.2) Pub Date : 2023-11-08 Giovanni Paolino, Andrea Carugno, Franco Rongioletti, Maurilio Ponzoni, Vincenzo Russo, Paolo Sena, Marco Ardigò, Antonio Costanzo, Santo Raffaele Mercuri, Mario Valenti
The occurrence of bone marrow metastases (BMM) in melanoma patients is often underestimated, with only 7% detected during in-vivo staging procedures but rising to 45% in autopsy cases. This systematic review aims to shed light on the clinical and laboratory features of BMM in melanoma by analyzing 73 studies selected from 2 482 initially retrieved from PubMed, Embase, and Cochrane CENTRAL databases
-
Melanomas and mast cells: an ambiguous relationship. Melanoma Res. (IF 2.2) Pub Date : 2023-11-02 Lisa M Kohl, Tina L Sumpter
Mast cells (MCs) accumulate in a broad range of tumors, including melanomas. While MCs are potent initiators of immunity in infection, and in allergic inflammation, the function of MCs in anti-melanoma immunity is unclear. MCs have the potential to release tumoricidal cytokines and proteases, to activate antigen-presenting cells and to promote anti-tumor adaptive immunity. However, within the immunosuppressive
-
Impact of anesthesia choice in cutaneous melanoma surgery. Melanoma Res. (IF 2.2) Pub Date : 2023-11-02 Matthew G K Benesch, Joseph J Skitzki
Invasive cutaneous melanoma is the most lethal skin cancer, but fortunately, the vast majority can be surgically treated with wide local excision, and sometimes additionally with sentinel or index lymph node biopsy for prognostication. Melanomas are particularly immunogenic malignancies, and preclinical studies have demonstrated that use of volatile anesthetics and opioids, unlike local agents, can
-
Correlations between inflammatory cytokine levels and degree of pigmentation in acral melanomas. Melanoma Res. (IF 2.2) Pub Date : 2023-11-02 Hong Euy Kim, Jinkyeong Kim, Hyung Keon Park, Jee-Bum Lee, Sook Jung Yun
Cutaneous melanoma, a highly aggressive skin tumor, is characterized by complex signaling pathways in terms of its pathogenesis and progression. Although the degree of pigmentation in melanoma determines its progression, metastasis, and prognosis, its association with inflammatory cytokines remains unclear. Thus, we evaluated the associations between melanoma pigmentation and plasma levels of inflammatory
-
Intratumoural and systemic inflammation as predictors for treatment response in BRAF-mutated melanoma patients under targeted therapies. Melanoma Res. (IF 2.2) Pub Date : 2023-11-02 Thilo Gambichler, Maria Iordanou, Jürgen C Becker, Laura Susok
Intratumoural as well as systemic inflammation in melanoma has thoroughly been studied in the context of patients treated with immune checkpoint inhibitors but not with BRAF/MEK inhibitors (BRAFi/MEKi). We aimed to study whether parameters of intratumoral and systemic inflammation correlate with clinical outcome in patients with BRAF-mutant metastatic melanoma treated with BRAFi/MEKi. We studied 51
-
Prognosis of CDKN2A germline mutation in patients with familial melanoma: a systematic review and meta-analysis. Melanoma Res. (IF 2.2) Pub Date : 2023-11-02 Ana Taibo, Sabela Paradela, Jorge Suanzes-Hernández, Vanesa Balboa-Barreiro, Javier Amado-Bouza, Eduardo Fonseca
Familial melanoma is defined as melanoma occurring in two or more first-degree relatives by the WHO. Germline mutations are isolated in a subset of them. It is well known that CDKN2A is the most frequently mutated high-risk gene in familial melanoma, however, the prognosis it confers to patients who carry its mutations is still controversial. This review aims to assess whether germline mutations imply
-
Rare immune-related adverse events in a patient with metastatic melanoma: a case report highlighting sarcoidosis-like reactions triggered by immune-checkpoint inhibitors. Melanoma Res. (IF 2.2) Pub Date : 2023-10-13 Yuanzhen Cao, Muhammad Zubair Afzal, Edward J Gutmann, Keisuke Shirai
Pembrolizumab and ipilimumab/nivolumab (ipi/nivo) combination are FDA-approved immune checkpoint inhibitor (ICI) therapies for metastatic melanoma. ICIs could result in various inflammation responses known as immune-related adverse events (IRAEs). We report a patient with metastatic melanoma who developed multiple IRAEs including sarcoidosis-like reaction (SLR), diabetic ketoacidosis (DKA), and worsening
-
Exploring the role of epigenetic alterations and non-coding RNAs in melanoma pathogenesis and therapeutic strategies. Melanoma Res. (IF 2.2) Pub Date : 2023-10-02 Marco Rubatto, Silvia Borriello, Nadia Sciamarrelli, Valentina Pala, Luca Tonella, Simone Ribero, Pietro Quaglino
Melanoma is a rare but highly lethal type of skin cancer whose incidence is increasing globally. Melanoma is characterized by high resistance to therapy and relapse. Despite significant advances in the treatment of metastatic melanoma, many patients experience progression due to resistance mechanisms. Epigenetic changes, including alterations in chromatin remodeling, DNA methylation, histone modifications
-
Uveitis associated with immune checkpoint inhibitors or BRAF/MEK inhibitors in patients with malignant melanoma. Melanoma Res. (IF 2.2) Pub Date : 2023-10-02 Ikuyo Sada, Yosuke Harada, Tomona Hiyama, Mina Mizukami, Takanobu Kan, Mikio Kawai, Yoshiaki Kiuchi
To evaluate the frequency and characteristics of uveitis associated with immune checkpoint inhibitors (ICIs) or BRAF/MEK inhibitors (B/MIs) in patients with malignant melanoma. Patients diagnosed with malignant melanoma who underwent radical or local resection for malignant melanoma, regardless of clinical stage or postoperative adjuvant therapy, at Hiroshima University Hospital from January 2015 to
-
The combination of PAC-1 and entrectinib for the treatment of metastatic uveal melanoma. Melanoma Res. (IF 2.2) Pub Date : 2023-09-22 Matthew W Boudreau, Emily J Tonogai, Claire P Schane, Min X Xi, James H Fischer, Jayanthi Vijayakumar, Yan Ji, Theodore M Tarasow, Timothy M Fan, Paul J Hergenrother, Arkadiusz Z Dudek
The treatment of metastatic uveal melanoma remains a major clinical challenge. Procaspase-3, a proapoptotic protein and precursor to the key apoptotic executioner caspase-3, is overexpressed in a wide range of malignancies, and the drug PAC-1 leverages this overexpression to selectively kill cancer cells. Herein, we investigate the efficacy of PAC-1 against uveal melanoma cell lines and report the
-
Safety of immune checkpoint inhibitors after proton beam therapy in head and neck mucosal melanoma: a case series. Melanoma Res. (IF 2.2) Pub Date : 2023-09-04 Mao Uematsu, Hiromichi Nakajima, Ako Hosono, Hikari Kiyohara, Akira Hirota, Nobuyuki Takahashi, Misao Fukuda, Shota Kusuhara, Takehiro Nakao, Chikako Funasaka, Chihiro Kondoh, Kenichi Harano, Nobuaki Matsubara, Yoichi Naito, Tetsuo Akimoto, Toru Mukohara
Proton beam therapy (PBT) has shown promising efficacy in treating locally advanced head and neck mucosal melanoma despite its poor prognosis. Although PBT may improve the efficacy of subsequent immune checkpoint inhibitors (ICIs), the safety of ICIs in patients who have previously received PBT has not been established. Hence, this study evaluated the safety of ICIs in patients who had recurrent mucosal
-
Recent advances of artificial intelligence in melanoma clinical practice. Melanoma Res. (IF 2.2) Pub Date : 2023-09-04 Zijun Lin, Haoyan Shen, Xinguang Liu, Wanrui Ma, Mingfa Wang, Jie Ruan, Hongbin Yu, Sha Ma, XueRong Sun
Skin melanoma is a lethal cancer. The incidence of melanoma is increasing rapidly in all regions of the world. Despite significant breakthroughs in melanoma treatment in recent years, precise diagnosis of melanoma is still a challenge in some cases. Even specialized physicians may need time and effort to make accurate judgments. As artificial intelligence (AI) technology advances into medical practice
-
Melanoma-specific survival in worse in the elderly: a multicentric cohort study. Melanoma Res. (IF 2.2) Pub Date : 2023-09-04 Sonia Segura, Sebastian Podlipnik, Aram Boada, Rosa M Martí, Mireia Sabat, Oriol Yélamos, Inés Zarzoso-Muñoz, Antoni Azón-Masoliver, Daniel López-Castillo, Joaquim Solà, Carola Baliu-Piqué, Loida Galvany-Rossell, Paola Pasquali, Miquel Just-Sarobé, Xavier Duran, Cristina Carrera, Nina A Richarz, Ramon M Pujol, Josep Malvehy, Susana Puig
We aimed to characterise cutaneous melanoma in the elderly and determine its association with poorer prognosis. We studied a prospective cohort of the melanoma population in Catalonia between 2012 and 2016. We compared young patient group (<75 years old) with elderly patient group (≥75 years old). We included 3009 patients (52.5% women) from 14 centres, with a mean age at diagnosis of 61.1 years. In
-
Telomere length is associated with increased risk of cutaneous melanoma: a Mendelian randomization study. Melanoma Res. (IF 2.2) Pub Date : 2023-08-25 Mingjuan Liu, Yining Lan, Hanlin Zhang, Xinyi Zhang, Mengyin Wu, Leyan Yang, Jia Zhou, Meiyi Tong, Ling Leng, Heyi Zheng, Jun Li, Xia Mi
The MR analysis using two TL GWAS datasets revealed strong and consistent evidence that long TL is causally associated with an increased risk of CM. The analysis of the Codd et al. dataset found that long TL significantly predicted an elevated risk of CM (IVW OR = 2.411, 95% CI 2.092-2.780, P = 8.05E-34). Similarly, the analysis of the Li et al. dataset yielded consistent positive results across all
-
Direct early growth response-1 knockdown decreases melanoma viability independent of mitogen-activated extracellular signal-related kinase inhibition. Melanoma Res. (IF 2.2) Pub Date : 2023-08-25 David R Miley, Cynthia M Andrews-Pfannkoch, Jose S Pulido, Samantha A Erickson, Richard G Vile, Michael P Fautsch, Alan D Marmorstein, Lauren A Dalvin
To investigate downstream molecular changes caused by mitogen-activated protein kinase (MEK) inhibitor treatment and further explore the impact of direct knockdown of early growth response-1 (EGR1) in melanoma cell culture. RNA-sequencing (RNA-Seq) was performed to determine gene expression changes with MEK inhibitor treatment. Treatment with MEK inhibitor (trametinib) was then assessed in two cutaneous
-
Mucosal melanoma: from molecular landscape to current treatment strategies. Melanoma Res. (IF 2.2) Pub Date : 2023-08-25 Jane Mattei, Eduardo N Trindade, Marcio F Chedid
Mucosal melanoma (MM) is an aggressive tumor originating from melanocytes located in the respiratory, gastrointestinal, and urogenital tract with clinical and pathologic characteristics distinct from cutaneous melanoma. In addition, MMs have a unique biology that contributes to delayed diagnosis and, therefore an adverse prognosis. The factors all contribute to a treatment paradigm unique from its
-
Cost-effectiveness analysis of an orphan drug-tebentafusp in patients with metastatic uveal melanoma and a call for value-based pricing. Melanoma Res. (IF 2.2) Pub Date : 2023-08-25 Shaohong Luo, Chen Xie, Ningning Lin, Dong Lin, Dian Gu, Shen Lin, Xiaoting Huang, Xiongwei Xu, Xiuhua Weng
The normative regimens recommendations for treating metastatic uveal melanoma (mUM) are absent in the US. Recently, a phase III randomized clinical trial revealed that tebentafusp yielded a conspicuously longer overall survival than the control group. Based on the prominent efficacy, this study aimed to assess whether tebentafusp is cost-effective compared to the control group in patients with untreated
-
Melanocytic neoplasms in neurofibromatosis type 1: a systematic review. Melanoma Res. (IF 2.2) Pub Date : 2023-08-14 Summer N Meyer, Elanee Simmons, Amy C Studer, Katherine A Rauen, Maija Kiurua
Neurofibromatosis type 1 (NF1) is commonly mutated in melanoma, yet the risk of melanoma in individuals with NF1 is incompletely understood. We performed a systematic review to investigate the risk and characteristics of melanoma and melanocytic nevi in NF1 individuals. PubMed was searched for articles describing NF1 individuals with melanoma, or melanocytic nevi. Those with cutaneous and ocular melanomas
-
pSTAT5 is associated with improved survival in patients with thick or ulcerated primary cutaneous melanoma. Melanoma Res. (IF 2.2) Pub Date : 2023-08-10 Samuel X Tan, Sharene Chong, Casey Rowe, Magdalena Claeson, James Dight, Chenhao Zhou, Mathieu P Rodero, Maryrose Malt, B Mark Smithers, Adele C Green, Kiarash Khosrotehrani
Identifying prognostic biomarkers to predict clinical outcomes in stage I and II cutaneous melanomas could guide the clinical application of adjuvant and neoadjuvant therapies. We aimed to investigate the prognostic value of phosphorylated signal transducer and activator of transcription 5 (pSTAT5) as a biomarker in early-stage melanoma. This study evaluated all initially staged Ib and II melanoma
-
Treatment experience with encorafenib plus binimetinib for BRAF V600-mutant metastatic melanoma: management insights for clinical practice. Melanoma Res. (IF 2.2) Pub Date : 2023-08-03 Kourtney Augustyn, Jocelyn Joseph, Anisha B Patel, Azadeh Razmandi, Amatul Noor Ali, Hussein A Tawbi
For patients with locally advanced or metastatic melanoma who have BRAF V600 activating mutations, combination therapy with BRAF and MEK inhibitors is now the standard of care. The combination of encorafenib, a highly selective adenosine triphosphate-competitive BRAF inhibitor, plus binimetinib, a potent, selective, allosteric, non-adenosine triphosphate-competitive MEK1/2 inhibitor, was approved by
-
Definitive treatment with PD-1 blockade and radiation therapy of unresected primary desmoplastic melanoma of the nose. Melanoma Res. (IF 2.2) Pub Date : 2023-08-03 Caroline A Gjorup, Ines Pires da Silva, Linda Martin, Jonathan R Stretch, Richard A Scolyer, Georgina V Long, Angela Hong
Two patients with primary desmoplastic melanoma of the nose were treated with definitive anti-PD-1 checkpoint inhibitor (anti-PD1) and radiation therapy. Both patients were technically resectable with partial rhinectomy but both declined for cosmetic reasons. The melanoma multidisciplinary team recommended that the patients receive PD1 blockade. The initial response to PD-1 blockade was temporary in
-
Lenalidomide arrests cell cycle and modulates PD1-dependent downstream mTOR intracellular signals in melanoma cells. Melanoma Res. (IF 2.2) Pub Date : 2023-07-12 Claudia Felici, Anna Passarelli, Paola Cafforio, Vito Racanelli, Patrizia Leone, Marco Tucci
Despite numerous efforts to define the best therapeutic strategies in advanced melanoma, the response of many patients remains heterogeneous and of short duration. Lenalidomide, an immunomodulating drug, has shown anti-inflammatory, antiangiogenic and anticancer properties in haematological disorders; however, few preclinical data support the rationale for using this drug in melanoma patients. In this
-
Estimating survival in patients with melanoma brain metastases: prognostic value of lactate dehydrogenase. Melanoma Res. (IF 2.2) Pub Date : 2023-07-03 Giacomo Pelizzari, Elisa Bertoli, Silvia Buriolla, Maria Grazia Vitale, Debora Basile, Lorenza Palmero, Diego Zara, Donatella Iacono, Freschi Andrea, Gaetano Pascoletti, Silvia Bolzonello, Mattia Garutti, Gianpiero Fasola, Fabio Puglisi, Alessandro Marco Minisini
Patients with melanoma brain metastases (MBM) have poor prognosis, albeit advances in locoregional and systemic treatments. The melanoma-specific Graded Prognostic Assessment (GPA) effectively stratifies survival for patients with MBM. Nevertheless, lactate dehydrogenase (LDH), a well known prognostic factor for patients with melanoma, is not represented in the GPA scores and might add prognostic information
-
Temporal correlation between the first melanoma and the first noncutaneous tumor in CKDN2A genotyped patients. Melanoma Res. (IF 2.2) Pub Date : 2023-06-21 Laura Cristina Gironi, Elia Esposto, Francesca Zottarelli, Roberto Giorgione, Pamela Farinelli, Elisa Zavattaro, Edoardo Cammarata, Nunzia Di Cristo, Paola Ogliara, Lara Camillo, Mara Giordano, Simona Mellone, Barbara Pasini, Alessandro Ambrosi, Paola Savoia
CDKN2A pathogenic variants are well known to be associated with cutaneous melanoma and noncutaneous tumors (NCTs). Herein, we investigated the temporal correlation between the first cutaneous melanoma and NCT both in CDKN2A mutation carriers (MUT) and in wild-type melanoma patients, a poorly explored issue to date. Two hundred forty-five cutaneous melanoma patients were genotyped for the CDKN2A gene
-
Durable control of metastases in an HLA-A2+ patient with refractory melanoma after low-dose radiotherapy in combination with MAGE-A4 T cell therapy: a case report. Melanoma Res. (IF 2.2) Pub Date : 2023-06-16 Kewen He, David S Hong, Danxia Ke, Partow Kebriaei, Tianjiao Wang, Hassan Danesi, Genevieve Bertolet, Carola Leuschner, Nahum Puebla-Osorio, Tiffany A Voss, Quan Lin, Elliot Norry, Paula M Fracasso, James W Welsh
There is no currently approved adoptive cellular therapy for solid tumors. Pre-clinical and clinical studies have demonstrated that low-dose radiotherapy (LDRT) can enhance intratumoral T cell infiltration and efficacy. This case report describes a 71-year-old female patient with rectal mucosal melanoma that had developed metastases to liver, lung, mediastinum, axillary nodes, and brain. After systemic
-
A glimpse at locally advanced melanomas in the settings of poverty: pathologists viewpoint. Melanoma Res. (IF 2.2) Pub Date : 2023-06-13 Wubshet Assefa, Serkadis Muluye, Andualem Assefa, Yacob Alemu
Cutaneous melanoma is the most aggressive cancer of the skin arising from pigment-producing cells, known as melanocytes. It is notorious for spreading early to distant locations. Survival of patients with melanoma largely depends on the thickness of the lesion at the primary site thus spotting it early is crucial. Early diagnosis of melanoma, with an improved quality of life and treatment outcomes
-
Expression of angiogenic and lymphangiogenic genes in primary cutaneous melanoma: relationship with angiolymphatic invasion and disease-free survival. Melanoma Res. (IF 2.2) Pub Date : 2023-06-12 Omar García-Pérez, Leticia Melgar-Vilaplana, Ines Sifaoui, Miguel-Ángel García-Bello, Elizabeth Córdoba-Lanús, Ricardo Fernández-de-Misa
Melanoma is one of the most common cancers in the world. The main routes of tumor progression are related to angiogenesis and lymphangiogenesis. These routes can occur by local invasion, which is called angiolymphatic invasion (ALI). In this study, we assess gene expression of relevant biomarkers of angiogenesis and lymphangiogenesis in 80 FFPE melanoma samples to determine a molecular profile that
-
Analysis of circulating tumor DNA during checkpoint inhibition in metastatic melanoma using a tumor-agnostic panel. Melanoma Res. (IF 2.2) Pub Date : 2023-06-12 Judit Kisistók, Ditte Sigaard Christensen, Mads Heilskov Rasmussen, Lone Duval, Ninna Aggerholm-Pedersen, Adam Andrzej Luczak, Boe Sandahl Sorensen, Martin Roelsgaard Jakobsen, Trine Heide Oellegaard, Nicolai Juul Birkbak
Immunotherapy has revolutionized treatment of patients diagnosed with metastatic melanoma, where nearly half of patients receive clinical benefit. However, immunotherapy is also associated with immune-related adverse events, which may be severe and persistent. It is therefore important to identify patients that do not benefit from therapy early. Currently, regularly scheduled CT scans are used to investigate
-
Efficacy of local ablative therapies in patients with solid tumors treated with immune checkpoint inhibitors and oligoprogression: a single-center analysis. Melanoma Res. (IF 2.2) Pub Date : 2023-06-05 Ahmet Anil Ozluk, Murat Karateke, Ulus Ali Sanli, Burcak Karaca
The concept of oligoprogression reflects a situation where a limited number of metastatic tumor sites have progressed and other metastatic sites are under control with current systemic therapy. The optimal management of oligoprogression remains unclear. In this retrospective study, we evaluated the contribution of local ablative treatment approaches after oligoprogression to progression-free survival
-
Assessment of lipid and pigment content in suspicious melanocytic lesions to improve melanoma detection. Melanoma Res. (IF 2.2) Pub Date : 2023-06-05 Shivkar V Amara, Nicole Grbic, Gabriella Melson, Candice E Brem, Nedaa Almier, Jag Bhawan, Rhoda M Alani, Marianne Collard
Melanoma is a highly aggressive form of skin cancer and the most frequent lethal malignancy diagnosed by dermatologists. Although there have been advances for predicting melanoma prognosis, there are few highly sensitive and specific diagnostic tools for clinically evaluating suspicious melanocytic lesions prior to biopsy. We have recently determined that alterations in cellular lipid and pigment content
-
Chemical features of melanoma tumor resident TRG CDR3s associated with better survival probabilities. Melanoma Res. (IF 2.2) Pub Date : 2023-05-23 Deo Rei L Agnila, Taha I Huda, Rachel A Eakins, Dhruv N Patel, Monica Hsiang, Andrea Chobrutskiy, Boris I Chobrutskiy, George Blanck
We assessed the T-cell receptor gamma (TRG) recombination reads from the cancer genome atlas melanoma tumor exome files and the TRG recombination reads from an independent, melanoma exome file dataset, from the Moffitt Cancer Center. TRG complementarity determining region-3 (CDR3) amino acid (AA) sequences were assessed for chemical complementarity to cancer testis antigens, with such complementarity
-
Nodular type predominance of head and neck cutaneous malignant melanoma in Asian populations leads to poor outcome and low survival. Melanoma Res. (IF 2.2) Pub Date : 2023-05-18 Hyokyung Yoo, Sunkyu Park, Sang Wha Kim
Cutaneous malignant melanomas of the head and neck (HNM) are proposed to have notable histological and clinical differences from those at other sites (other melanoma); however, HNMs among Asians have remained poorly understood. This study aimed to investigate the clinicopathological features and prognostic factors of HNM in Asians. Asian melanoma patients who underwent surgical treatment from January